Sutro Biopharma (STRO) Income from Continuing Operations (2017 - 2026)
Sutro Biopharma (STRO) posted Income from Continuing Operations of 46756000.0 for Q4 2025, up 17.77% sequentially from 56857000.0 in Q3 2025, and up 35.46% YoY from 34516915.4 in Q4 2024.
Powered by 
Analysis
Sutro Biopharma (STRO) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Income from Continuing Operations for 9 years, with the latest figure at 46756000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 35.46% year-over-year to 46756000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 182737000.0 (up 19.66% YoY) and the FY2025 annual result came in at 191080000.0, up 15.99% from the prior year.
- Income from Continuing Operations climbed to 46756000.0 in Q4 2025 per STRO's latest filing, from 56857000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 31057000.0 in Q4 2023 and troughed at 72443000.0 in Q4 2024.
- A 5-year average of 36552600.0 and a median of 38817000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations jumped 189.78% in 2023, then tumbled 333.26% in 2024.
- Over 5 years, Income from Continuing Operations stood at 38125000.0 in 2021, then climbed by 9.26% to 34594000.0 in 2022, then surged by 189.78% to 31057000.0 in 2023, then plunged by 333.26% to 72443000.0 in 2024, then surged by 35.46% to 46756000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 46756000.0, 56857000.0, and 11499000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Sutro Biopharma | 336.40 Mn | 172.06 Mn | - | -38.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.53 Mn |
| Dec 31, 2025 | -6.71 Mn |
| Sep 30, 2025 | -56.86 Mn |
| Jun 30, 2025 | -11.50 Mn |
| Mar 31, 2025 | -65.33 Mn |
| Dec 31, 2024 | -72.48 Mn |
| Sep 30, 2024 | -48.79 Mn |
| Jun 30, 2024 | -48.02 Mn |
| Mar 31, 2024 | -58.21 Mn |
| Dec 31, 2023 | 31.06 Mn |
| Sep 30, 2023 | -49.28 Mn |
| Jun 30, 2023 | -38.52 Mn |
| Mar 31, 2023 | -50.05 Mn |
| Dec 31, 2022 | -34.59 Mn |
| Sep 30, 2022 | -19.49 Mn |
| Jun 30, 2022 | -26.01 Mn |
| Mar 31, 2022 | -39.11 Mn |
| Dec 31, 2021 | -38.13 Mn |
| Sep 30, 2021 | -30.90 Mn |
| Jun 30, 2021 | -6.15 Mn |